These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 29370102)

  • 21. Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico Techniques.
    Di Lello P; Pastor R; Murray JM; Blake RA; Cohen F; Crawford TD; Drobnick J; Drummond J; Kategaya L; Kleinheinz T; Maurer T; Rougé L; Zhao X; Wertz I; Ndubaku C; Tsui V
    J Med Chem; 2017 Dec; 60(24):10056-10070. PubMed ID: 29166018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compounds.
    Yu JL; Chen TT; Zhou C; Lian FL; Tang XL; Wen Y; Shen JK; Xu YC; Xiong B; Zhang NX
    Acta Pharmacol Sin; 2016 Jul; 37(7):984-93. PubMed ID: 27238211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mass spectrometry for fragment screening.
    Chan DS; Whitehouse AJ; Coyne AG; Abell C
    Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Fragment-Based Ligand Screen Against Part of a Large Protein Machine: The ND1 Domains of the AAA+ ATPase p97/VCP.
    Chimenti MS; Bulfer SL; Neitz RJ; Renslo AR; Jacobson MP; James TL; Arkin MR; Kelly MJ
    J Biomol Screen; 2015 Jul; 20(6):788-800. PubMed ID: 25690569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant Kinase Production and Fragment Screening by NMR Spectroscopy.
    Han B; Ahn HC
    Methods Mol Biol; 2016; 1360():35-46. PubMed ID: 26501900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Practical aspects of NMR-based fragment discovery.
    Zartler ER; Mo H
    Curr Top Med Chem; 2007; 7(16):1592-9. PubMed ID: 17979770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-Based Virtual Screening.
    Li Q; Shah S
    Methods Mol Biol; 2017; 1558():111-124. PubMed ID: 28150235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fragment-based screening by protein-detected NMR spectroscopy.
    Kerber PJ; Nuñez R; Jensen DR; Zhou AL; Peterson FC; Hill RB; Volkman BF; Smith BC
    Methods Enzymol; 2023; 690():285-310. PubMed ID: 37858532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
    Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
    J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fragment-Based Ligand Designing.
    Katiyar SP; Malik V; Kumari A; Singh K; Sundar D
    Methods Mol Biol; 2018; 1762():123-144. PubMed ID: 29594771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NMR in target driven drug discovery: why not?
    Keiffer S; Carneiro MG; Hollander J; Kobayashi M; Pogoryelev D; Ab E; Theisgen S; Müller G; Siegal G
    J Biomol NMR; 2020 Nov; 74(10-11):521-529. PubMed ID: 32901320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introduction to fragment-based drug discovery.
    Erlanson DA
    Top Curr Chem; 2012; 317():1-32. PubMed ID: 21695633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The rise of fragment-based drug discovery.
    Murray CW; Rees DC
    Nat Chem; 2009 Jun; 1(3):187-92. PubMed ID: 21378847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Applications of (19)F-NMR in Fragment-Based Drug Discovery.
    Norton RS; Leung EW; Chandrashekaran IR; MacRaild CA
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two 'Golden Ratio' indices in fragment-based drug discovery.
    Orita M; Ohno K; Niimi T
    Drug Discov Today; 2009 Mar; 14(5-6):321-8. PubMed ID: 19028598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
    Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
    Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fragment-based lead discovery and design.
    Joseph-McCarthy D; Campbell AJ; Kern G; Moustakas D
    J Chem Inf Model; 2014 Mar; 54(3):693-704. PubMed ID: 24490951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A three-stage biophysical screening cascade for fragment-based drug discovery.
    Mashalidis EH; Śledź P; Lang S; Abell C
    Nat Protoc; 2013 Nov; 8(11):2309-24. PubMed ID: 24157549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [NMR in the fragment-based drug discovery].
    Hanzawa H; Takizawa T
    Tanpakushitsu Kakusan Koso; 2009 Sep; 54(12 Suppl):1617-21. PubMed ID: 21089597
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.